Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

Raltitrexed (Tomudex), a thymidylate synthase inhibitor, is an alternative to 5-fluorouracil (5-FU)/leucovorin (LV) for the first-line treatment of advanced colorectal cancer. Following the completion of four phase III studies with raltitrexed at the recommended dose of 3.0 mg/m(2), it is opportune...

Full description

Bibliographic Details
Main Authors:	Cunningham, D, Zalcberg, J, Maroun, J, James, R, Clarke, S, Maughan, T, Vincent, M, Schulz, J, González Barón, M, Facchini, T
Format:	Journal article
Language:	English
Published:	2002

Similar Items

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
by: Vadiaka Maria, et al.
Published: (2002-01-01)

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
by: Popov, I, et al.
Published: (2008)

Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics
by: Justin G. Rosch, et al.
Published: (2020-02-01)

Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
by: Liu X, et al.
Published: (2023-03-01)

Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids
by: Lisi Zeng, et al.
Published: (2021-08-01)

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation
by: D Hind, et al.
Published: (2008-05-01)

Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report
by: Montserrat Carreres-Prieto, et al.
Published: (2015-01-01)

Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
by: Ke Cheng MD, PhD, et al.
Published: (2022-02-01)

Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
by: Xichao Dai, et al.
Published: (2023-08-01)

Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells
by: Wen-Xiu Ding, et al.
Published: (2019-02-01)

Final results of the PETACC-1 trial of bolus 5-FU/LV vs raltitrexed: An unsuccessful story?
by: Popov, I, et al.
Published: (2008)

Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
by: Sheng Li MD, et al.
Published: (2024-08-01)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
by: Shao W, et al.
Published: (2019-11-01)

A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
by: Lloyd Jones, et al.
Published: (2001-01-01)

Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by upregulating RSK4
by: Cong Hu, et al.
Published: (2022-08-01)

Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial
by: Weibing Leng, et al.
Published: (2025-02-01)

Efficacy and safety of raltitrexed plus S-1 regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study
by: Yu-Wen Zhou, et al.
Published: (2022-05-01)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
by: Yonghua Bi, et al.
Published: (2023-02-01)

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases
by: Ai-Wei Feng, et al.
Published: (2022-09-01)

Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial
by: Shiguang Chen, et al.
Published: (2024-10-01)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
by: Hongchao Zhen, et al.
Published: (2023-03-01)

Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
by: Yu Cheng, et al.
Published: (2024-09-01)

Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
by: Yonghua Bi, et al.
Published: (2022-01-01)

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis
by: Yonghua Bi, et al.
Published: (2022-07-01)

SALIRI‐based (raltitrexed plus irinotecan) therapy as a second‐line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non‐interventional, registry study
by: Shuqui Qin, et al.
Published: (2024-08-01)

Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design
by: Thomas Bast, et al.
Published: (2022-12-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization
by: Yanfang Wu, et al.
Published: (2022-09-01)

Oxcarbazepine Monotherapy
by: J Gordon Millichap
Published: (2006-10-01)

Raltitrexed versus 5‐fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial
by: Pengwei Yan, et al.
Published: (2020-09-01)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
by: Cheng-Jiang Liu, et al.
Published: (2021-01-01)

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
by: N. N. Babyshkina, et al.
Published: (2022-11-01)

Effectiveness and tolerability of perampanel monotherapy in children with newly diagnosed focal epilepsy
by: Fen Zhao, et al.
Published: (2023-05-01)

Topiramate Monotherapy in Epilepsy
by: J Gordon Millichap
Published: (2009-09-01)

Efficacy and safety of raltitrexed-eluting CalliSpheres bead transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma: a single-arm, prospective study
by: Zhanguo Sun, et al.
Published: (2024-02-01)

Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial
by: Xiaoying Zhao, et al.
Published: (2023-09-01)

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
by: Calne, R, et al.
Published: (1998)

Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
by: Qiao Yu, et al.
Published: (2023-01-01)

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY
by: V. Pullarkat, et al.
Published: (2022-06-01)

Targeted therapies in the management of Colorectal cancer
by: Maughan, T
Published: (2011)